

Lenacapavir Sustained Delivery Formulation Supports 6-Month Dosing Interval




Hans-Jürgen Stellbrink¹, Rebecca Begley², Justin Lutz², Martin Rhee², Hadas Dvory-Sobol², Anna Chiu², Steve K. West², Jessica Corpus², John Ling², Polina German²

Gilead Sciences, Inc., Foster City, CA, USA

Background

- Lenacapavir (LEN; GS-6207) is a novel, first-inclass, selective inhibitor of HIV-1 capsid protein (CA)
- LEN is being developed as a component of a longacting treatment regimen for people living with HIV (PLWH), including those with multiclass drug resistance (Begley et al. 2019, Yant et al. 2019)
- LEN has demonstrated potent antiviral activity in PLWH, with up to 2.3-log₁₀ copies/mL decline in HIV
- RNA over 10 d after a single subcutaneous (SC) dose (Daar et al. 2020, Sager et al. 2019)
- Both oral (Begley et al. 2020) and SC LEN formulations are in clinical development
- The present study is the first to assess the safety and single ascending-dose pharmacokinetics (PK) of a new SC LEN formulation designed to support a 6-month (q6mon) dosing interval
- This new SC LEN formulation, combined with an oral PK loading regimen, is administered q6mon in the ongoing Phase 2 and 3 clinical studies (ClinicalTrials.gov NCT04143594 and NCT04150068)



 $\mathsf{EC}_{\mathsf{so}},$ half-maximal effective concentration; Gag, group-specific antigen; Pol, polymeras

 Inhibition of multiple CA-dependent functions essential for viral replication

Objectives

 To assess the safety, tolerability, and PK of escalating single doses of SC LEN injectable solutions compared with placebo (PBO)

Methods

Study Design

LEN Dose: 300-mg/mL SC Solution	Total Volume (injection no. and volume)	Participants, n (active:PBO)	
300 mg	1.0 mL (1 x 1.0 mL)	8:2	
900 mg	3.0 mL (3 x 1.0 mL)	8:2	
900 mg	3.0 mL (2 x 1.5 mL)	8:2	

- Phase 1, blinded, placebo-controlled, randomized (4:1), single ascending-dose study in HIV negative participants
- Blinded safety and available PK data reviewed between ascending single-dose cohorts
- Safety assessments: adverse event (AE) monitoring, clinical laboratory values, physical examination, and electrocardiographic evaluations performed throughout the study
- PK assessments and analysis:
- -PK sampling performed through 449 d postdose
- Plasma concentrations of LEN determined using validated liquid chromatography-tandem mass spectrometry assays
- –LEN PK parameters estimated using noncompartmental methods (Phoenix[®] WinNonlin[®] Validation Suite[™] 7.0, Certara USA, Inc., Princeton, New Jersey, USA) and summarized using descriptive statistics

Results

Participant Enrollment and Demographics

	LEN 300 mg or PBO (1 x 1.0 mL)	LEN 900 mg or PBO (3 x 1.0 mL)	LEN 900 mg or PBO (2 x 1.5 mL)	
Enrolled/completed, n	10/10	10/10	10/10	30/30
Median age, y (range)	39 (26-45)	34 (21-44)	42 (25-44)	37 (21-45)
Men, n (%)	8 (80)	8 (80)	5 (50)	21 (70)
White, n (%)	4 (40)	9 (90)	8 (80)	21 (70)
Hispanic/Latino, n (%)	10 (100)	10 (100)	9 (90)	29 (97)
Median BMI, kg/m² (range)	28 (20-30)	27 (24-29)	25 (21-29)	27 (20-30)


BMI, body mass index.

LEN Pharmacokinetic Parameters

PK Parameter Mean (%CV)*	300 mg (1 × 1.0 mL) n=8	900 mg (3 × 1.0 mL) n=8	900 mg (2 × 1.5 mL) n=8
AUC _{sc} , h-ng/mL	66,400 (27.8)	225,000 (33.6)	224,000 (31.5)
AUC _{ket} , h-ng/mL	61,100 (28.8)	179,000 (53.4)	153,000 (47.6)
%AUC	8.06 (51.2)	5.79 (50.6)	21.5 (33.8)
C _{nea} , ng/mL	17.7 (50.3)	67.0 (54.8)	61.2 (43.5)
T _{man} , d	97.9 (55.8, 140)	77.1 (70.0, 84.2)	84.2 (62.9, 112)
T _{lent} , d	364 (334, 364)	280 (168, 280)	196 (196, 196)
t ₁₂ , d	175 (68.3, 93.8)	49.6 (46.7, 59.2)	64.6 (49.2, 80.0)

*Presented to 3 significant figures as mean and % coefficient of variation (CV), except time to maximal concentration ($C_{m,i}$, $T_{m,j}$), time of last measurable concentration ($T_{m,i}$), and half lift ($I_{m,i}$) median (quartiles 1, 3). AUC, area under curve from time to $t_{0} \leftrightarrow AUC_{m,i}$ AUC extrapolated between AUC, and AUC to last measurable concentration (AUC_m).

Mean LEN Single-Dose Plasma Concentration-Time Profiles



*Protein-adjusted EC_{ss}: macrophages, 1.16 ng/mL; CD4+ T cells, 2.32 ng/mL; and MT-4 cells, 3.87 ng/mL.(Yant SR, 2019) IQ, ratio of LEN plasma concentration/EC_{ss}: SD, standard

 Following administration of LEN 900 mg, concentrations were ≥24 ng/mL for 26 wk, corresponding to a mean IQ
≥6 (range 6.2–20.3 across in vitro assays) throughout a 26-wk (6-mon) dosing interval

LEN Pharmacokinetic Results Summary

- LEN exposures increased in a generally doseproportional manner from 300 to 900 mg
- \bullet LEN T_{_max} was 11–14 wk postdose and apparent $t_{_{1/2}}$ ranged from 7 to 11 wk
- A slow initial release of LEN was observed and target plasma concentrations were sustained for ≥6 mon after 900-mg single dose
- Similar PK was observed following 900-mg dose administered as 3 x 1.0-mL or 2 x 1.5-mL SC injection

LEN Safety Summary: Blinded Data*

AEs: ≥5 Participants, n (%)	LEN 300 mg or PBO (1 x 1.0 mL) n=10	LEN 900 mg or PBO (3 x 1.0 mL) n=10	LEN 900 mg or PBO (2 x 1.5 mL) n=10	Overall N=30
Injection-site induration	3 (30)	8 (80)	10 (100)	21 (70)
Injection-site pain	0	6 (60)	8 (80)	14 (47)
Injection-site erythema	1 (10)	5 (50)	4 (40)	10 (33)
Headache	3 (30)	4 (40)	3 (30)	10 (33)
Injection-site swelling	0	4 (40)	4 (40)	8 (27)
Injection-site nodule	2 (20)	3 (30)	0	5 (17)

1 participant had Grade 3 AEs of abscess (serious AE), cellulitis, and methicillin-resistant Staphylococcus aureus infection, none of which were related to LEN.

Overall, LEN was well tolerated

- No serious or Grade 2, 3, or 4 AEs related to study drug
- No AEs leading to discontinuation
- Injection-site reactions were common (80%), but all were mild (Grade 1) and mostly lasted only a few days; induration and nodules were generally

Results Cont'd

- detectable only by clinicians and lasted several weeks
- 7 participants (23%) had Grade 3 or 4 laboratory abnormalities; none were clinically relevant


Simulations Supporting Phase 2/3 LEN Dosing Regimen

- Based on observed antiviral activity, (Daar et al. 2020) the mean LEN target concentration is 24 ng/mL, corresponding to a mean IQ ≥6 (range 6.2–20.3)
- The new LEN 300-mg/mL SC injection formulation exhibits a slow initial release necessitating an oral PK loading regimen prior to the first injection
- PK simulations were performed using single-dose oral LEN tablet PK (Begley et al. 2020) and SC injection PK from the present study
- The regimen was predicted to achieve target concentrations within a few days of initiation of dosing and maintain them with a 26-wk (6-mon) dosing interval

LEN Oral + SC Dosing Regimen in Ongoing Phase 2 and 3 Studies



Predicted LEN PK for Phase 2/3 Oral + SC Combination Regimen



Conclusions

- Single LEN SC doses up to 900 mg were generally safe and well tolerated
- Injection-site reactions were common, but all were mild
- LEN 900 mg SC maintained target concentrations for 26 wk (6 mon), supporting its use as a q6mon antiretroviral agent
- PK simulations support LEN regimen with oral PK loading, followed by q6mon SC maintenance in ongoing Phase 2 and 3 clinical studies
- –14-d oral loading: 600 mg on Days 1 and 2, and 300 mg on Day 8
- –SC maintenance: 900 mg on Day 15, followed by 900-mg q6mon

References

Begley R, et al. CROI 2020, poster 3670 Begley R, et al. EACS 2019, oral PS-13/1 Daar E, et al. CROI 2020, poster 3691 Sager JE, et al. CROI 2019, abstr 14/1 Yant SR, et al. CROI 2019, poster 480

Acknowledgments

We extend our thanks to the participants. This study was funded by Gilead Sciences, Inc.

Disclosures: R. Begley, J. Lutz, M. Rhee, H. Dvory-Sobol, A. Chiu, S.K. West, J. Corpus, J. Ling, and P. German: Gilead.